FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
What happened
FDA inspected GenoGenix’s Boca Raton, Florida facility from July 14, 2025, to July 18, 2025, and issued a Form FDA 483 plus an amended Form FDA 483. FDA found sterile drug products made under insanitary conditions and multiple CGMP failures, plus subpotent products, an NAD+ lot with excessive bacterial endotoxins after three patients developed adverse symptoms, unapproved new drugs, and 503B reporting and labeling failures. The firm ceased drug production and distribution and on July 30, 2025 recalled sterile products within expiry due to lack of sterility assurance or microbial contamination.
What FDA found
Drug products intended or expected to be sterile were prepared under insanitary conditions that could contaminate them.
section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]The firm did not establish or follow written procedures to prevent microbiological contamination of sterile drugs or validate aseptic and sterilization processes.
21 CFR 211.113(b)The firm released injectable methylcobalamin 5,000 mcg/mL at 65.3% of label and injectable B Complex with dexpanthenol at 43.1% of label.
section 501(c) of the FDCA [21 U.S.C. § 351(c)]An unopened vial of NAD+ lot GG121624-023 contained 3,360 EU/mL bacterial endotoxins after three patients developed low blood pressure, shaking, shivers, and body aches and went to the emergency room.
section 501(c) of the FDCA [21 U.S.C. § 351(c)]The firm had no FDA-approved applications for compounded drugs or for repackaged semaglutide, tirzepatide, retatrutide, and Thymosin Beta-4.
sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a), 331(d)]; PHS Act section 351 [42 U.S.C. § 262] for Thymosin Beta-4The firm compounded with 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and NAD+, which are not on the 503B bulks list and were not on the drug shortage list.
section 503B(a)(2)(A)(i) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]
What FDA wants
FDA asks GenoGenix to correct the cited violations and provide adequate corrective action documentation; no response deadline is stated in the provided letter.
Who should pay attention
- clinics and patients receiving compounded sterile injectables
- outsourcing facilities and compounding pharmacies
- companies repackaging or selling GLP-1 drugs such as semaglutide and tirzepatide
This is a summary. Read the original letter on fda.gov.